Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 71,500 shares, a drop of 21.5% from the February 13th total of 91,100 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average trading volume of 36,300 shares, the days-to-cover ratio is presently 2.0 days.

Daré Bioscience Price Performance

NASDAQ:DARE traded up $0.09 during trading hours on Tuesday, reaching $2.97. 11,879 shares of the company were exchanged, compared to its average volume of 45,958. The business has a 50 day moving average of $3.13 and a 200 day moving average of $3.32. Daré Bioscience has a 1-year low of $2.67 and a 1-year high of $7.56. The company has a market capitalization of $25.84 million, a P/E ratio of -5.03 and a beta of 1.38.

Institutional Trading of Daré Bioscience

Several large investors have recently modified their holdings of the stock. AMH Equity Ltd raised its stake in Daré Bioscience by 50.0% in the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 50,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in Daré Bioscience by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares during the period. Renaissance Technologies LLC raised its position in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Daré Bioscience during the 4th quarter worth approximately $52,000. 6.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday, December 17th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.